Travere therapeutics submits new drug application for sparsentan for the treatment of iga nephropathy

San diego, march 21, 2022 (globe newswire) -- travere therapeutics, inc. (nasdaq: tvtx) today announced that it has submitted a new drug application (nda) to the u.s. food and drug administration (fda) under subpart h for accelerated approval of sparsentan for the treatment of iga nephropathy (igan).

TVTX Ratings Summary

TVTX Quant Ranking